Printer Friendly

LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR

 LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
 LA JOLLA, Calif., April 13 /PRNewswire/ -- LIDAK Pharmaceuticals


(NASDAQ: LDAKU, LDAKA) announced today that Stuart A. Samuels was elected as a new director at a meeting of the board of directors held April 11, 1992.
 Samuels previously held key executive positions with Rorer Pharmaceuticals where from 1986 to 1990 he served as senior vice president. In this capacity, Samuels served as general manager of Rorer Pharmaceuticals, the U.S. prescription drug division and president of Dermik Laboratories, the dermatology division of Rorer Pharmaceuticals Corp. From 1980 to 1986 Samuels served in various executive marketing positions for the Revlon Health Care Group. Prior to joining Revlon, Samuels held management positions at the Warner Lambert Company and Fisher-Stevens Inc. Presently, Samuels, who is 50 years old, serves as an independent consultant for the pharmaceutical industry.
 LIDAK Pharmaceuticals is attempting to develop and commercialize pharmaceutical and other commercially significant products for the health care industry. LIDAK is currently focusing its efforts on the commercialization of LIDAKOL (tm) as a treatment for herpes and other indications. In addition the company is developing its Large Multivalent Immunogen technology as potential new therapies against cancer and viral diseases, and its Free Fatty Acid technology as a possible clinical diagnostic assay for the prediction, diagnosis and monitoring of cancer and diabetes. Finally, its Human Immune System Reconstituted SCID mouse technology is being used for evaluating new potential anti-AIDS drugs and potential new diagnostic and treatment approaches to cancer.
 -0- 4/13/92
 /CONTACT: Michael H. Lorber, VP/CFO of LIDAK Pharmaceuticals, 619-558-0364; or Roger Pondel of Pondel Parsons and Wilkinson, 310-207-9300, for LIDAK Pharmaceuticals/
 (LDAKU LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER


CH -- LA015 -- 7821 04/13/92 13:48 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:292
Previous Article:STAN WEST MINING ANNOUNCES ACQUISITION OF OUTSTANDING SHARES OF FIRST INTERNATIONAL ACCEPTANCE CORP.
Next Article:SKOLNIKS ANNOUNCES SUCCESSFUL COMPLETION OF ITS EXCHANGE OFFER


Related Articles
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS AND CHIRON ENTER INTO COLLABORATIVE RESEARCH AGREEMENT ON AIDS
LIDAK PHARMACEUTICALS TO REDEEM CLASS A WARRANTS
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS RECEIVES NOTICES OF ALLOWANCE ON TWO U.S. PATENTS FOR THE TREATMENT OF ARTHRITIS
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK Pharmaceuticals Adds New Vice President and Reports Drug Development Highlights at Annual Meeting
LIDAK Pharmaceuticals Receives New Patent Allowance On Human Immune System in Non-Human Animal
LIDAK Pharmaceuticals and Shareholders Committee Reach Settlement Agreement, Postpone Annual Shareholders' Meeting

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters